Diabetes associated with immune checkpoint inhibition: presentation and management challenges.

Galligan, A; Xu, W; Fourlanos, S; Nankervis, A; Chiang, C; Mant, A M; Parente, P; Rischin, D; Krishnamurthy, B; Sandhu, S; Colman, P G

Galligan, A; Xu, W; Fourlanos, S; Nankervis, A; Chiang, C; Mant, A M; Parente, P; Rischin, D; Krishnamurthy, B; Sandhu, S; Colman, P G.

Afiliación

Galligan A; Department of Diabetes and Endocrinology, Royal Melbourne Hospital.
Xu W; Division of Cancer Medicine, Peter MacCallum Cancer Centre.
Fourlanos S; Department of Diabetes and Endocrinology, Royal Melbourne Hospital.
Nankervis A; Department of Diabetes and Endocrinology, Royal Melbourne Hospital.
Chiang C; Department of Diabetes and Endocrinology, Royal Melbourne Hospital.
Mant AM; Division of Cancer Medicine, Peter MacCallum Cancer Centre.
Parente P; Cancer Services, Eastern Health, Monash University.
Rischin D; Cancer Services, Eastern Health, Monash University.
Krishnamurthy B; Division of Cancer Medicine, Peter MacCallum Cancer Centre.
Sandhu S; Sir Peter MacCallum Department of Oncology, University of Melbourne.
Colman PG; St Vincent's Institute, Melbourne, Australia.

Diabet Med ; 2018 Jun 16.

Article en En | MEDLINE | ID: mdl-29908076

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Año: 2018 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Año: 2018 Tipo del documento: Article